Dr Reddys Laboratories launches Cinacalcet tablet in US

Dr Reddy’s Laboratories Limited informed via a press filing on Thursday that it has launched Cinacalcet tablets in the US market.  

The drug is a therapeutic equivalent generic version of Sensipar (Cinacalcet) tablets, approved by United States Food & Drug Administration (USFDA).

The drug is used to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis. Sensipar is a trademark of Amgen Inc.

According to IQVIA Health data, the Sensipar brand and the generic market had United States sales of approximately USD 312 million MAT for the most recent twelve months ending in July 2020.

Dr Reddy’s Cinacalcet tablets are made available in 30 mg, 60 mg, and 90 mg tablets in a bottle count size of 30.

Today, the market is closed on the occasion of Gandhi Jayanti. On Thursday, the share of Dr Reddy’s Laboratories closed 1.41 per cent down at Rs 5,113.8 on BSE. In comparison, S&P BSE Healthcare index closed 0.44 per cent up. The stock trades at a P/E of 25.82 on BSE. It has recorded a 52-week high of Rs 5,514.65 and a 52-week low of Rs 2,497.6 on BSE.